Loading…
← CockpitCompetitor Analysis › ASND Ascendis Pharma A/SOpen in the cockpit ↗

Ascendis Pharma A/SASNDCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Danish biotech using its TransCon sustained-release technology for growth-hormone and endocrine-disease drugs.

Momentum leader 80
Mkt cap
$16.9B
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$177M
20-day average traded
Fwd P/E
28.0×
forward earnings
ROIC−WACC
+11.1 pp
WACC 7.0%
Hurdle
-133 pp
Req g minus delivered
Next earnings
91 days
17 Feb 2027
Close · USD$270.33
1D-0.3%
1W+4.3%
1M+15.4%
3M+6.1%
6M+12.0%
YTD+26.8%
1Y+24.8%
ATR %2.7%
Beta0.40
52w lowhigh4.2% off high

What Ascendis Pharma A/S does

Danish biotech using its TransCon sustained-release technology for growth-hormone and endocrine-disease drugs.

Sells its medicines itself in the US and Europe to specialist doctors, and relies on partners such as Visen in China, paid through upfront, milestone and royalty payments. Its TransCon technology attaches a drug to a carrier that releases it slowly, giving long-acting dosing, and the same engine is used to build new products.

Products and services

  • Skytrofa (growth hormone deficiency)
  • Yorvipath (hypoparathyroidism)
  • Oncology/rare-disease pipeline

Customers

  • Endocrinologists
  • Pediatric specialists
  • Payers

Where it sits in the supply chain

  • Pharmaceuticals
  • Biotech
  • Endocrinology - growth hormone, rare…

What could go right

  • Skytrofa/Yorvipath share gains from convenient dosing
  • Pipeline expansion using the TransCon platform

What could go wrong

  • Reimbursement/pricing pressure in rare disease
  • Execution risk scaling multiple launches at once

Moat: narrow (IP / patents, process know-how). Proprietary TransCon prodrug technology gives longer-acting dosing than older daily therapies.

Headquarters: Copenhagen, Denmark · Founded: 2006

Named competitors

Ascendis Pharma A/S at a glance

Size Ascendis Pharma A/S (ASND) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $16.9B, the 551st largest of 3,085 United States companies the cockpit tracks. Shares closed at $270.33 on 18 Nov 2026.

Performance Over six months the shares gained 12.0%, against +4.4% for the median peer and -2.2% for the United States market (cap-weighted) — 7th highest of 21 in its peer set.

Growth Revenue grew 93.8% over the last twelve months (peer median +18.9%); the operating margin is 18.4% (peer median 23.1%).

Valuation It trades at 28.0× forward earnings against a peer median of 23.6× (9th most expensive of 20).

Price implies For today's price to make sense, revenue must grow about 19% a year for seven years (Req g). Recent delivered growth is +152%, so the hurdle is -133 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 11.1 points above its cost of capital (7.0% WACC).

Short interest Short interest is 4.6% of the free float (30 Oct 2026).

Next results Next results expected around 17 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026ASND 109Peer median 105
Six months, rebased to 100: Ascendis Pharma A/S against the median of its 20 peers (local-currency closes).

Ascendis Pharma A/S financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$1.40B$813M$393M$288M$53.8M
Revenue growth—+107%+36%+436%—
Gross profit$1.27B$691M$333M$225M$25.7M
EBITDA$278M-$134M-$282M-$472M-$572M
Net income$1.02B-$257M-$409M-$520M-$613M
Free cash flow$598M$51.3M-$333M-$508M-$536M
Capital expenditure$19.7M$9.58M$1.54M$2.64M$15.2M
Total debt$509M$1.02B$887M$712M$543M

Quarterly statements and history in the cockpit →

Ascendis Pharma A/S competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%+60%-10%0%+10%EXEL4507SOBIJAZZORNAVTORNTPHARM18016446000538688506ALNYLAURUSLABS6990ZYDUSLIFESIGDRREDDYVTRS1177RECASND6-month return →1-month return →
Up and to the right = strong over both horizons. Ascendis Pharma A/S is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%+200%0×500×1,000×EXEL4507SOBITORNTPHARM180164466990SIGASNDRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Ascendis Pharma A/S is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%+150%0%50%100%150%EXEL4507ORNAVTORNTPHARM18016446ALNYLAURUSLABS6990SIGDRREDDYVTRSASNDGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Ascendis Pharma A/S is the large dot.

Ascendis Pharma A/S competitors and peer comparison

Head to head with its named competitors (ASND vs NOVO-B.CO vs PFE vs IPN.PA)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Ascendis Pharma A/S ASND$16.9B+12%+94%18%28.0×19.2%
Novo Nordisk A/S NOVO-B.CO$177B-6%+6%48%11.8×-0.5%
Pfizer PFE$160B+9%+1%26%9.9×-4.3%
Ipsen IPN.PA$14.8B+1%+14%30%10.8×-6.7%
BioMarin Pharmaceutical BMRN$11.9B+22%+20%19%11.2×8.2%
BridgeBio Pharma BBIO$15.2B+14%+167%-37%n/an/a
Takeda Pharmaceutical 4502.T$69.8B+30%+6%18%51.0×3.7%

How Ascendis Pharma A/S compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Ascendis Pharma A/S against its 20 peers (data as of 18 Nov 2026)
MeasureASNDPeer medianRank in peer set
1-month return+15.4%+5.7%2nd highest of 21
6-month return+12.0%+4.4%7th highest of 21
Distance from 52-week high-4.2%-7.2%5th highest of 21
Revenue growth (TTM)+93.8%+18.9%2nd highest of 21
Operating margin18.4%23.1%9th lowest of 21
Forward P/E28.0×23.6×9th most expensive of 20
Growth the price implies (Req g, 7 yrs)19.2%0.8%7th most demanding of 19
Growth delivered (Del g)+152.4%+12.3%highest of 19
Hurdle (Req g minus delivered)-133.2 pp-11.2 ppleast demanding of 19
ROIC minus cost of capital+11.1 pp+7.2 pp7th highest of 21
EV / EBITDA58.6×16.0×most expensive of 18
Net debt / EBITDA-2.1×1.1×3rd least indebted of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Ascendis Pharma A/S ASNDUnited States$16.9B+12%+94%18%28.0×19.2%+152.4%
Exelixis EXELUnited States$16.7B+37%+9%40%17.7×-3.8%+18.6%
Shionogi & 4507.TJapan$17.6B+3%+46%29%11.8×0.2%+11.0%
Swedish Orphan Biovitrum SOBI.STSweden$16.1B+6%+15%30%24.1×-2.1%+13.1%
Jazz Pharmaceuticals Public JAZZUnited States$15.9B+4%+13%25%9.3×-2.8%+12.5%
Orion ORNAV.HEFinland$15.7B+41%+34%38%23.6×-6.2%+11.7%
Torrent Pharmaceuticals TORNTPHARM.NSIndia$18.8B+3%+42%22%70.2×37.6%+11.3%
Innovent Biologics 1801.HKHong Kong$18.9B+4%+43%17%52.3×11.6%+26.8%
PharmaEssentia 6446.TWTaiwan$15.0B+67%+78%40%31.9×23.7%+94.8%
Yunnan Baiyao 000538.SZChina$15.0B+11%+5%11%18.3×-0.2%+4.7%
Sichuan Biokin Pharmaceutical 688506.SSChina$14.9B-7%+14%-43%n/an/an/a
Ipsen IPN.PAFrance$14.8B+1%+14%30%10.8×-6.7%+7.2%
Alnylam Pharmaceuticals ALNYUnited States$20.0B-50%+56%20%21.2×0.5%+49.8%
Laurus Labs LAURUSLABS.NSIndia$13.4B+73%+23%24%76.4×51.2%+7.3%
Sichuan Kelun-Biotech Biopharmaceutical 6990.HKHong Kong$13.0B-1%+44%-38%1,176.1×55.3%+33.6%
Zydus Lifesciences ZYDUSLIFE.NSIndia$12.8B+18%+24%17%30.0×n/an/a
Sigma Healthcare SIG.AXAustralia$22.4B+2%+209%9%38.4×28.9%+26.1%
Dr. Reddy's Laboratories DRREDDY.NSIndia$12.5B+5%-4%9%32.0×30.7%+12.1%
Viatris VTRSUnited States$23.3B+23%+5%11%7.5×11.2%+3.7%
Sbp 1177.HKHong Kong$12.2B+5%+15%30%17.5×-5.7%+5.4%
Recordati REC.MIItaly$12.0B+3%+8%30%16.6×1.1%+12.6%

Questions

Who are Ascendis Pharma A/S's main competitors?
Named competitors: Novo Nordisk (NOVO-B.CO), Pfizer (PFE), Ipsen (IPN.PA), BioMarin Pharmaceutical (BMRN), BridgeBio Pharma (BBIO), Takeda Pharmaceutical (4502.T). The cockpit's measured peer set (industry) also includes Exelixis (EXEL), Shionogi & (4507.T), Swedish Orphan Biovitrum (SOBI.ST), Jazz Pharmaceuticals Public (JAZZ), Orion (ORNAV.HE), Torrent Pharmaceuticals (TORNTPHARM.NS).
Is Ascendis Pharma A/S expensive compared with its peers?
On forward p/e it trades at 28.0× against a peer median of 23.6×, 9th most expensive of 20 in its peer set. For today's price to make sense, revenue must grow about 19% a year for seven years (Req g). Recent delivered growth is +152%, so the hurdle is -133 pp: the price already allows for a slowdown.
How has Ascendis Pharma A/S stock performed?
Over six months to 18 Nov 2026 the shares returned +12.0% against +4.4% for the median peer; over one year +24.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.